Precision Medicine in Oncology®

Selpercatinib demonstrated a favorable safety profile, characterized by low-grade treatment-emergent adverse effects, manageable early onset toxicity, and low rates of treatment discontinuation, in patients with RET-altered advanced solid tumors.

Paz Polak, PhD, discusses research that evaluated cancer genomes in Ghana through the use of liquid biopsies.

The CDK9 inhibitor voruciclib demonstrated early activity as a single agent in KRAS-mutant cancer cell lines, and synergistically inhibited growth of KRAS-mutant cancers when used in combination with sotorasib and adagrasib in preclinical models.

Conflicting results regarding the benefit of adjuvant CDK4/6 inhibition in early-stage hormone receptor–positive, HER2-negative breast cancer have prompted many questions regarding patient selection and treatment duration, which many hope will be answered with ongoing biomarker research.

The FDA has approved a new biweekly dosing regimen of 500 mg/m2 as a 120-minute intravenous infusion for cetuximab (Erbitux) for patients with KRAS wild-type, EGFR-expressing colorectal cancer or squamous cell carcinoma of the head and neck.

Tanya Dorff, MD, discusses how the FDA approvals of olaparib and rucaparib have paved the way for additional research with PARP inhibitors in metastatic castration-resistant prostate cancer.

Ulrich Steidl, MD, PhD, discusses translational research efforts that have been made with targeting leukemia stem cells and ongoing clinical trials that are examining novel therapeutic targets in myeloid malignancies and beyond.

The RET inhibitor TPX-0046 demonstrated encouraging preliminary activity, which included objective responses, and an acceptable toxicity profile when used in patients with RET-driven advanced solid tumors.

Thomas C. Krivak, MD, discusses the significance of HRD in ovarian cancer, approved and prospective HRD tests, and considerations for genomic testing in this population.

Janakiraman Subramanian, MD, discusses the efficacy of selpercatinib in patients with RET fusion–positive non–small cell lung cancer.

The FDA has granted a breakthrough therapy designation to the FGFR inhibitor futibatinib for the treatment of patients with previously treated, locally advanced or metastatic cholangiocarcinoma that harbors FGFR2 gene rearrangements, including fusions.

Digital media, now more than ever, has become a primary platform for communication, and in 2020, the production of the OncLive® podcast, OncLive On Air™, was put into overdrive to bring practicing oncologists exclusive biweekly interviews, discussions, and insights from leading experts in cancer care.

Gilteritinib was found to result in a significant improvement in overall survival when used in patients with FLT3-mutated, relapsed/refractory acute myeloid leukemia, meeting the primary end point of the confirmatory phase 3 COMMODORE trial in China.

Osimertinib (Tagrisso) showcased encouraging efficacy and acceptable safety in patients with EGFR-positive, advanced non–small cell lung cancer. according to real-world findings from an observational, multicenter study.

Adagrasib yielded durable responses and broad disease control, in addition to providing extensive predicted coverage throughout the dosing interval, in patients with KRAS G12C–mutant advanced non–small cell lung cancer.

The fatty acid synthase inhibition caused by AZ12756122 could represent a promising therapeutic alternative to overcome resistance to EGFR TKIs because of the synergistic interaction that it has with osimertinib and its ability to reduce cancer stem cell properties in EGFR-mutant non–small cell lung cancer cell models.

The FDA has granted 2 breakthrough device designations to cover new intended uses of the Signatera molecular residual disease test developed by Natera, Inc.

Although Ki-67 is a commonly used measure of cellular proliferation in breast cancer tissue, its utility as a biomarker for helping to guide therapy decisions has been clouded by technical and clinical questions.

Circulating tumor DNA is working to transform care in colorectal cancer and beyond and positivity is actionable at this time.

Dr. Spira discusses the historical challenges of targeting KRAS, key findings from the phase 2 CodeBreaK 100 trial with sotorasib in KRAS G12C-mutant solid tumors, and the next steps of development for KRAS inhibitors in oncology.

Janakiraman Subramanian, MD, discusses the depth and durability of responses that have been reported with selpercatinib and pralsetinib, as well as ongoing research focused on improving outcomes and overcoming resistance mechanisms in RET fusion–positive NSCLC.

Lara A. Kujtan, MD, discusses the data that support the current utility of osimertinib in EGFR-mutant NSCLC and where else it is currently being explored.

The FDA has granted a fast track designation to poziotinib for use in previously treated patients with HER2 exon 20 mutations.

Dr. Levy discusses key research efforts with targeted therapies for patients with lung cancer who harbor NTRK, KRAS, and HER2 aberrations.

Melissa L. Johnson, MD, discusses the implications of recent advances made in the development of oncogenetargeted agents in non–small cell lung cancer.